An excerpt of Metabolic dysfunction and alcohol-related liver disease: position statement by an expert panel on alcohol-related liver disease
10.3760/cma.j.cn311367-20250213-00061
- VernacularTitle:《代谢功能障碍和酒精相关性肝病：酒精相关肝病专家小组的立场声明》摘译
- Author:
Yiwei SHANG
1
;
Guohong HAN
1
Author Information
1. 西安国际医学中心医院消化内科，西安 710100
- Publication Type:Journal Article
- Keywords:
Non-alcoholic fatty liver;
Alcohol-related liver disease;
Alcoholic liver disease;
Alcoholic cirrhosis
- From:
Chinese Journal of Digestion
2025;45(4):217-222
- CountryChina
- Language:Chinese
-
Abstract:
This position statement explores the intricate relationship between alcohol intake and metabolic dysfunction in the context of the 2023 nomenclature for steatotic liver disease (SLD). Recent and lifetime alcohol use should be accurately assessed in all patients with SLD to facilitate classification of alcohol use in grams of alcohol per week. Alcohol biomarkers (phosphatidylethanol), use of validated questionnaires, and collateral information from friends and relatives could help facilitate differentiation between alcohol-related liver disease per se and liver disease with both metabolic and alcohol-related liver disease. Heavy alcohol use can contribute to cardiometabolic risk factors such as high blood pressure, hypertriglyceridemia, and hyperglycemia. As a result, caution should be exercised in the application of only one metabolic dysfunction criterion to diagnose metabolic dysfunction-associated steatotic liver disease, as suggested in the 2023 nomenclature document, particularly in individuals exceeding weekly alcohol use thresholds of 140 g for women and 210 g for men. Additionally, metabolic dysfunction and alcohol use should be reassessed over time. This approach could ensure a more accurate prognosis and effective management of SLD addressing both metabolic and alcohol-related factors.
